Quarterly Results, Profit & Loss, Balance Sheet, Cash Flows, and Ratios are shown below as separate sections.
Financials of Glaxosmi. Pharma
Quarter-by-quarter operating performance
| Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 787 | 762 | 957 | 805 | 930 | 815 | 1,011 | 949 | 974 | 805 | 980 | 1,041 | 995 |
| Expenses + | 618 | 618 | 668 | 587 | 673 | 584 | 689 | 658 | 641 | 554 | 644 | 670 | 644 |
| Operating Profit | 170 | 144 | 289 | 218 | 257 | 231 | 322 | 292 | 333 | 251 | 336 | 371 | 351 |
| OPM % | 22% | 19% | 30% | 27% | 28% | 28% | 32% | 31% | 34% | 31% | 34% | 36% | 35% |
| Other Income + | 38 | 54 | 28 | -135 | 32 | 36 | 39 | 35 | 41 | 44 | 36 | 50 | 36 |
| Interest | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 1 | 1 | 1 |
| Depreciation | 17 | 16 | 18 | 17 | 18 | 16 | 17 | 19 | 15 | 16 | 17 | 20 | 13 |
| Profit before tax | 190 | 181 | 299 | 65 | 271 | 249 | 344 | 308 | 359 | 279 | 354 | 400 | 373 |
| Tax % | 30% | 27% | 27% | 30% | 28% | 27% | 27% | 25% | 27% | 27% | 27% | 26% | 26% |
| Net Profit + | 133 | 132 | 218 | 46 | 194 | 182 | 252 | 230 | 263 | 205 | 257 | 296 | 278 |
| EPS in Rs | 7.88 | 7.81 | 12.84 | 2.70 | 11.48 | 10.76 | 14.91 | 13.57 | 15.52 | 12.10 | 15.20 | 17.45 | 16.40 |
Financials of Glaxosmi. Pharma
Annual income statement trend
| Mar 2015 15m | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 3,305 | 2,838 | 2,908 | 2,871 | 3,128 | 3,224 | 2,926 | 3,278 | 3,252 | 3,454 | 3,749 | 3,822 |
| Expenses + | 2,672 | 2,360 | 2,489 | 2,363 | 2,527 | 2,567 | 2,327 | 2,516 | 2,447 | 2,545 | 2,570 | 2,512 |
| Operating Profit | 633 | 478 | 420 | 508 | 601 | 657 | 598 | 762 | 804 | 909 | 1,179 | 1,309 |
| OPM % | 19% | 17% | 14% | 18% | 19% | 20% | 20% | 23% | 25% | 26% | 31% | 34% |
| Other Income + | 149 | 125 | 119 | 70 | 131 | -262 | 9 | 1,401 | 103 | -21 | 149 | 166 |
| Interest | 0 | 0 | 0 | 0 | 1 | 6 | 4 | 2 | 2 | 2 | 1 | 3 |
| Depreciation | 25 | 25 | 27 | 38 | 49 | 83 | 79 | 68 | 66 | 70 | 67 | 66 |
| Profit before tax | 756 | 578 | 511 | 540 | 683 | 306 | 525 | 2,093 | 839 | 816 | 1,260 | 1,406 |
| Tax % | 37% | 35% | 34% | 35% | 35% | 70% | 32% | 19% | 27% | 28% | 26% | 26% |
| Net Profit + | 476 | 376 | 337 | 351 | 445 | 93 | 358 | 1,695 | 611 | 590 | 928 | 1,036 |
| EPS in Rs | 28.12 | 22.20 | 19.88 | 20.70 | 26.29 | 5.50 | 21.14 | 100.04 | 36.05 | 34.83 | 54.75 | 61.15 |
| Dividend Payout % | 111% | 113% | 75% | 85% | 76% | 727% | 142% | 90% | 89% | 92% | 99% | 93% |
Financials of Glaxosmi. Pharma
Capital structure and asset base
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 85 | 85 | 85 | 85 | 169 | 169 | 169 | 169 | 169 | 169 | 169 | 169 |
| Reserves | 1,744 | 2,099 | 1,922 | 1,973 | 1,970 | 1,651 | 1,309 | 2,494 | 1,572 | 1,608 | 1,782 | 2,098 |
| Borrowings + | 3 | 2 | 2 | 1 | 1 | 0 | 35 | 20 | 16 | 19 | 10 | 33 |
| Other Liabilities + | 1,384 | 869 | 995 | 1,889 | 1,771 | 1,315 | 1,602 | 1,950 | 1,570 | 1,760 | 2,147 | 2,023 |
| Total Liabilities | 3,216 | 3,055 | 3,004 | 3,947 | 3,911 | 3,136 | 3,115 | 4,633 | 3,327 | 3,557 | 4,108 | 4,324 |
| Fixed Assets + | 123 | 204 | 258 | 325 | 432 | 758 | 387 | 331 | 330 | 321 | 284 | 281 |
| CWIP | 115 | 268 | 605 | 923 | 1,003 | 120 | 13 | 30 | 20 | 14 | 14 | 33 |
| Investments | 0 | 6 | 0 | 0 | 0 | 0 | 0 | 366 | 518 | 813 | 1,118 | 1,392 |
| Other Assets + | 2,977 | 2,577 | 2,140 | 2,700 | 2,477 | 2,257 | 2,715 | 3,907 | 2,458 | 2,408 | 2,692 | 2,618 |
| Total Assets | 3,216 | 3,055 | 3,004 | 3,947 | 3,911 | 3,136 | 3,115 | 4,633 | 3,327 | 3,557 | 4,108 | 4,324 |
Financials of Glaxosmi. Pharma
Operating, investing and financing cash movement
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operating Activity + | 338 | 139 | 234 | 473 | 409 | 490 | 578 | 811 | 484 | 582 | 1,290 | 903 |
| Cash from Investing Activity + | 180 | 499 | 301 | -104 | -153 | -57 | 418 | -406 | 808 | 9 | -46 | 397 |
| Cash from Financing Activity + | -497 | -638 | -511 | -307 | -358 | -428 | -696 | -524 | -1,543 | -562 | -769 | -737 |
| Net Cash Flow | 21 | -0 | 24 | 62 | -102 | 6 | 300 | -119 | -251 | 29 | 475 | 563 |
| Free Cash Flow | 175 | -69 | -24 | 639 | 166 | 336 | 536 | 2,371 | 451 | 573 | 1,273 | 849 |
| CFO/OP | 93% | 72% | 94% | 133% | 101% | 103% | 121% | 122% | 93% | 92% | 116% | 93% |
Financials of Glaxosmi. Pharma
Working capital efficiency and return ratios
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 11 | 16 | 21 | 19 | 14 | 11 | 27 | 23 | 22 | 23 | 28 | 26 |
| Inventory Days | 91 | 156 | 111 | 147 | 131 | 135 | 159 | 144 | 131 | 144 | 126 | 124 |
| Days Payable | 74 | 97 | 73 | 149 | 109 | 100 | 135 | 156 | 122 | 171 | 186 | 154 |
| Cash Conversion Cycle | 27 | 75 | 60 | 17 | 36 | 46 | 50 | 11 | 31 | -4 | -31 | -4 |
| Working Capital Days | -48 | 26 | 7 | -90 | -72 | -38 | -39 | -94 | -57 | -64 | -99 | 42 |
| ROCE % | 42% | 29% | 22% | 26% | 31% | 33% | 38% | 37% | 36% | 51% | 63% | 65% |
Expansion plans supported by capex of INR 200-250 crores annually, with 60% towards expansion/new products and 40% towards efficiency improvements. Key concall…
The company is confident of achieving 20%+ volume growth backed by steady ramp-up in Jammu and existing facilities. Key concall takeaways from Innova Captab…
Chronic respiratory segment in India showing over 25% growth; oncology and cardiovascular segments also strong. Key concall takeaways from Glenmark…
markets continue to be broad-based growth drivers, with 17% YoY growth and expansion in B2B and B2C markets including Europe, UK, Nordics, Africa, LATAM, MENA…